News
News
September 2025
Following its successful selection for a Stage 1 Kick by Venture Kick, Alterbiotix receives its second financial and entrepreneurial support Kick. For more information, please visit Finance.
Alterbiotix announces that it has been selected for a Stage 1 Kick by Venture Kick, a Swiss organization supporting Swiss startups. For more information, please visit Finance.
April 2025
Alterbiotix will be attending the Swiss Biotech Day event to be held in Basel, Switzerland between May 5-6, 2025.
February 2025
An international patent application comprising composition of matter claims on different peptide structures, their use for prevention or treatment of infection by Streptococcus pneumoniae and combinations with several classes of anti-bacterial drugs has been filed.
December 2024
Alterbiotix announces that it has been selected for Stage 1 funding by INCATE, a non-profit organization funding promising early ventures in the Antimicrobial Resistance (AMR) field. For more information, For more information, please visit Finance.
May 2024
Scientific Reports publishes a publication authored by Prof. Lucy Hathaway describing the mechanism of action of V11A by identifying gene expression changes in multiple pathways. The observed changes are consistent with the growth suppression potential of V11A. For more information, please visit Publications.
April 2024
Communications Biology publishes a pivotal publication authored by Prof. Lucy Hathaway focusing on the discovery and validation of V11A, a new peptide with therapeutic potential for the treatment of pneumococcal diseases. V11A, imported by the AmiA-AliA/AliB permease, suppresses growth of multiple clinical isolates, including antibiotic resistant strains, while avoiding bacterial lysis and dysbiosis. For more information, please visit Publications.